Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Dermato-Onco2024 | Risk stratification and disease monitoring using ctDNA in cutaneous melanoma

Gabriele Roccuzzo • 31 Oct 2024

Dermato-Onco2024

Melanoma Skin Cancer

Gabriele Roccuzzo, MD, University of Turin, Turin, Italy, comments on the future role of circulating tumor DNA (ctDNA) as a clinical biomarker for disease status in patients with cutaneous melanoma. He emphasizes the need for further data from prospective randomized clinical trials before confirming the prime-time use of ctDNA in clinical practice. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.